NCT07639658
Temple Massager System Study in Women Ages 35-65
Not Yet Recruiting
Not specifiedAges 35–65ObservationalMOQ Collective, Ltd
~48 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Temple Massager System
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score
Measured over Baseline (Day 1) to End-of-Study (Day 35)
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Colleen Quinn · PRINCIPAL_INVESTIGATOR · MOQ Collective, Ltd
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Female, aged 35-65 years old, inclusive
Self-reported experience of daily stress, anxiety, tension headaches, facial tension, or TMJ-related discomfort
Headache frequency of 2 or more per week (self-reported)
If taking any prescription medication including SSRIs, anxiolytics, sleep medications, hormonal therapies, or blood pressure medications, must be on a stable dose for at least 4 weeks prior to study enrollment and throughout the course of the study
In good general health at the time of screening (Investigator discretion)
Able to read and understand English
Able to read, understand, and provide informed consent
Able to use a personal smartphone or tablet and access the study platform for daily data entry
Able to receive shipment of the study product at an address within the United States
Willing and able to use the Temple Massager System daily for 4 weeks
Exclusion
No personal smartphone or tablet, no internet access, or unwilling to use the study platform
Known allergy or sensitivity to lavender oil, mango butter, shea butter, arnica, or St. John's Wort (Note: lavender sensitivity alone is not exclusionary; an aromatherapy sensitivity protocol applies)
Active skin infection or open wounds on the face or temple area
Diagnosed trigeminal neuralgia or other cranial nerve pathology
Diagnosed vascular issues affecting the head or face: temporal arteritis, aneurysm, or cerebrovascular malformations
Bleeding disorders: history of easy bruising or bleeding in the face/head area, or current use of prescribed blood thinners (anticoagulants) such as Warfarin or Eliquis
Any surgery on the jaw, temples, or face within the last 6 months
Active inflammation: current redness, swelling, or extreme tenderness specifically over the temple arteries
Current use of prescription headache medications (triptans, topiramate, muscle relaxants, beta-blockers for migraine prophylaxis, or other prescription medications taken primarily for headache management)
Participants currently taking any prescribed medication for sleep or anxiety must be on a stable dose (no dose changes within the past 30 days) to be eligible; participants not on a stable dose are excluded
Current participation in another interventional study
Diagnosed Generalized Anxiety Disorder (GAD)
Currently pregnant, planning to become pregnant during the study period, or breastfeeding
Planned surgical procedure during the study period
Significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes
Unlikely for any reason to be able to comply with the study or considered unsuited for participation by the Principal Investigator
What this trial measures
- Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total ScoreBaseline (Day 1) to End-of-Study (Day 35)
The GAD-7 is a 7-item self-report questionnaire measuring emotional wellbeing on a 4-point Likert scale (0-3) per item with a 2-week recall window. Total score range: 0 to 21. Higher scores indicate greater symptom severity (worse outcome). In this study, the GAD-7 is used as a measure of subclinical emotional wellbeing, not as a diagnostic tool.